SAB Biotherapeutics, Inc.SABSNASDAQ
Loading
EPS Growth Under PressureDecelerating
Percentile Rank20
Studio
Year-over-Year Change

Year-over-year earnings per share growth rate

Percentile
P20
Within normal range
vs 3Y Ago
-62.4x
Contraction
Streak
1 qtr
Consecutive declineDecelerating
PeriodValue
Q4 2025-156.10%
Q3 2025490.83%
Q2 2025-94.64%
Q1 202554.47%
Q4 2024-9.82%
Q3 2024-41.77%
Q2 2024-46.30%
Q1 202486.01%
Q4 2023-297.94%
Q3 202328.68%
Q2 20236.85%
Q1 20236.41%
Q4 20222.50%
Q3 2022-44.14%
Q2 2022-582.61%
Q1 2022105.60%
Q4 2021-5380.00%
Q3 202188.97%
Q2 2021-312.50%
Q1 202115338.10%
Q4 20200.00%